Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 4/20 | 0.37 |
| ▸ | CNR2 | P34972 | 4/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18215221 | 1.00 | GAA (0.38) | GAACNR1CNR2CES2CES1 | |
| SCHEMBL13871008 | 1.00 | GAA (0.38) | GAACNR1CNR2CES2CES1 | |
| SCHEMBL8136342 | 0.98 | GAA (0.39) | GAACNR1CNR2CES2CES1 | |
| SCHEMBL12640536 | 0.93 | PTGS2 (0.38) | GAACES2CES1PTGS2SIGMAR1 | |
| SCHEMBL13193029 | 0.86 | EPHX1 (0.53) | NAAAEGFR | |
| SCHEMBL2631387 | 0.86 | KCNH3 (0.33) | CNR1CNR2SIGMAR1 | |
| SCHEMBL15686651 | 0.86 | KCNH3 (0.33) | CNR1CNR2SIGMAR1 | |
| SCHEMBL15686638 | 0.86 | KCNH3 (0.33) | CNR1CNR2SIGMAR1 | |
| SCHEMBL15686603 | 0.86 | KCNH3 (0.33) | CNR1CNR2SIGMAR1 | |
| SCHEMBL15686642 | 0.86 | KCNH3 (0.33) | CNR1CNR2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732470-B2 | Compositions and methods for the treatment of renal and cardiovascular disease | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2010-06-08 | — | — | US | disclosed |
| US-20080153889-A1 | Compositions and Methods for the Treatment of Renal and Cardiovascular Disease | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153889-A1 | Compositions and Methods for the Treatment of Renal and Cardiovascular Disease | REN, ALOX5, ALOX15B | GAA 1019/4885CNR1 2239/4885CNR2 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.